ImmuneCyte, Inc.
Chris Xu is an accomplished leader in the life sciences sector, currently serving as the Chairman of HealthBanks Biotech, a CDMO biomanufacturer and premier cell banking network, since July 2019. In addition, Chris Xu functions as a Venture Advisor at WI Harper Group, focusing on life science investments. As the Chairman and CEO of ThermoGenesis Holdings, Inc., since March 2016, Chris Xu oversees a market leader in automated cellular processing technologies. Furthermore, Chris Xu is a member of the Board of Directors at Peking University and holds the position of Adjunct Professor at the Institute of Molecular Medicine. Previously, Chris Xu founded and chaired Boyalife, a diversified life science holding company, from July 2009 to November 2016. Educational credentials include a PhD in Immunology from Washington University School of Medicine in St. Louis and an Executive MBA from Emory University's Goizueta Business School.
This person is not in any teams
ImmuneCyte, Inc.
ImmuneCyte is a multilingual, clinical-stage biopharmaceutical firm dedicated to the study and creation of alternative cell and gene medicines, such as CAR-NK, mononuclear, and T cells with chimeric antigen receptors, for the treatment of cancer, vascular, orthopaedic, and age-related illnesses. They have developed technological cell-based genetreatments on this platform to treat severe cases of b-thalassemia, a fatal blood genetic condition.